Skip to content

BSX · BOSTON SCIENTIFIC CORP

35 filings

10-K

BSX 10-K Annual Reports

BOSTON SCIENTIFIC CORP - 35 annual reports

Filing record · 2016–202610-K1310-Q328-K181

2025
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2025
Boston Scientific Corporation (BSX) reported a strong financial performance for the year ended December 31, 2025, with reported net sales increasing by 19.9% to $20.074 billion and reported net income attributable to common stockholders growing by 56.4% to $2.898 billion. This growth was primarily driven by robust commercial execution across its key business segments, particularly the Electrophysiology unit, fueled by the continued success of the FARAPULSE™ Pulsed Field Ablation System. The company also saw significant contributions from its Cardiovascular and Urology segments. Looking ahead, Boston Scientific announced its definitive agreement to acquire Penumbra, Inc. for approximately $14.5 billion, a strategic move expected to enhance its presence in the thrombectomy market. The company also completed several key acquisitions during the year, including Bolt Medical, SoniVie Ltd., and Intera Oncology, Inc., further strengthening its product portfolio and market position. With a solid cash position and access to credit facilities, the company believes it has sufficient liquidity to fund its operations, strategic initiatives, and upcoming acquisitions.
Feb 17, 2026
2024
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2024
Boston Scientific Corporation (BSX) reported strong financial performance for the fiscal year ended December 31, 2024. Net sales increased significantly by 17.6% to $16.747 billion, driven by robust commercial execution across all business units, particularly the Electrophysiology segment benefiting from the successful launch and rapid adoption of the Farapulse™ Pulsed Field Ablation System. The company also completed strategic acquisitions, including Axonics, Inc. and Silk Road Medical, Inc., which are expected to contribute to future growth. Profitability saw a substantial increase, with reported net income attributable to common stockholders reaching $1.853 billion ($1.25 per diluted share). On an adjusted basis, which excludes certain charges and credits, net income was $3.725 billion ($2.51 per diluted share). The company maintained a strong balance sheet and positive cash flow from operations, indicating effective management of resources and strategic investments. BSX continues to focus on innovation and expanding its global presence, positioning itself for continued growth in the medical technology sector.
Feb 18, 2025
2023-A
BOSTON SCIENTIFIC CORP Annual Report (Amendment), Year Ended Dec 31, 2023
Boston Scientific Corporation (BSX) has filed its 2023 Annual Report (10-K/A) on February 20, 2024, reflecting their performance for the period ending December 30, 2023. While the provided excerpt focuses on exhibit information, a full 10-K filing would detail the company's financial performance, strategic initiatives, risk factors, and management's discussion and analysis. Investors should review the complete filing to understand BSX's revenue growth, profitability trends, debt levels, and any significant changes in its product portfolio or market position. Key areas for investor attention in the full report typically include the company's performance across its various segments (e.g., Cardiovascular, MedSurg, Pelvic Health, Neuromodulation), any notable acquisitions or divestitures, ongoing research and development efforts, and the competitive landscape. The filing also contains crucial information on the company's outlook and forward-looking statements, which are essential for assessing future growth prospects and potential risks.
Feb 21, 2024
2023
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2023
Boston Scientific Corporation (BSX) reported a strong fiscal year 2023 with net sales reaching $14.24 billion, a 12.3% increase compared to 2022. This growth was driven by robust organic net sales growth of 12.3% and strategic acquisitions, demonstrating the company's diversified product portfolio and effective commercial execution across its MedSurg and Cardiovascular segments. Financially, the company reported a net income of $1.57 billion ($1.07 per diluted share) for 2023. On an adjusted basis, excluding certain charges and credits, adjusted net income was $3.00 billion ($2.05 per diluted share), highlighting operational improvements and strategic reinvestments. The company also strengthened its balance sheet, with significant operating cash flow and a healthy leverage ratio, positioning it well for future growth and strategic initiatives, including the pending acquisition of Axonics, Inc.
Feb 20, 2024
2022
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2022
Boston Scientific Corporation (BSX) reported strong net sales growth of 6.7% to $12.68 billion for the fiscal year ended December 31, 2022. This growth was driven by a combination of operational expansion, strategic acquisitions, and a diverse product portfolio, particularly in the Cardiovascular and MedSurg segments. Despite facing headwinds from foreign currency fluctuations and global supply chain challenges, the company demonstrated resilience. Financially, BSX reported a net income of $642 million, or $0.45 per diluted share. On an adjusted basis, excluding certain charges and credits, net income was $2.46 billion, or $1.71 per diluted share. The company maintained a robust balance sheet with $928 million in unrestricted cash and cash equivalents and a strong credit facility. The company's strategic imperatives focus on strengthening category leadership, expanding into high-growth adjacencies, and driving global expansion, which are supported by ongoing investments in research and development.
Feb 23, 2023
2021
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2021
Boston Scientific Corporation (BSX) reported a significant increase in net sales for the year ended December 31, 2021, reaching $11.888 billion, a 19.9% increase compared to 2020. This growth was primarily driven by the recovery of elective and semi-emergent medical procedures, which were impacted by the COVID-19 pandemic in the prior year. The company's strategic acquisitions, including Preventice Solutions, Farapulse, and Lumenis's global surgical business, also contributed positively to the sales performance. While the company reported a net income of $985 million ($0.69 per diluted share), adjusted net income, excluding certain charges and credits, was $2.336 billion ($1.63 per diluted share), reflecting strong operational performance. The company's gross profit margin improved to 68.8% in 2021, up from 65.0% in 2020, attributed to higher sales volumes and a favorable product mix, though offset by inflationary pressures on raw materials and freight. Looking ahead, Boston Scientific is focused on its strategic imperatives, including strengthening category leadership and expanding into high-growth adjacencies. The company maintains a strong liquidity position with $1.925 billion in unrestricted cash and cash equivalents. However, ongoing challenges include managing supply chain disruptions, potential increases in costs, and navigating a dynamic regulatory and reimbursement landscape. The company also reported substantial litigation-related charges, particularly concerning transvaginal surgical mesh products. Despite these challenges, BSX demonstrated resilience and a clear growth trajectory in 2021, driven by its diverse product portfolio and strategic initiatives.
Feb 23, 2022
2020
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2020
Boston Scientific Corporation's (BSX) 2020 Form 10-K filing reveals a challenging year impacted by the COVID-19 pandemic, which led to a 7.7% decrease in net sales, reaching $9.91 billion. The company reported a net loss of $82 million for the year. Despite the revenue decline, BSX demonstrated resilience through strategic cost management and a focus on its core product franchises across MedSurg, Rhythm and Neuro, and Cardiovascular segments. The company continues to invest in research and development to drive innovation and maintain its competitive edge in the medical device market. Key strategic imperatives include strengthening category leadership and expanding into high-growth adjacencies. BSX also made progress in its sustainability initiatives and diversity, equity, and inclusion efforts, underscoring its commitment to corporate social responsibility. The divestiture of its Specialty Pharmaceuticals business is planned for the first half of 2021, aiming to streamline operations and focus on its core medical device portfolio.
Feb 23, 2021
2019
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2019
Boston Scientific Corporation's 2019 10-K filing highlights a year of robust growth, driven significantly by strategic acquisitions, most notably BTG plc. The company reported net sales of $10.735 billion, an increase of 9.3% over the prior year, with operational growth of 11.1%. This growth was broadly distributed across its key segments, including Cardiovascular and MedSurg, with notable contributions from product launches and advancements in structural heart therapies and peripheral interventions. The company's financial performance was impacted by various charges and credits, including acquisition-related costs and a significant deferred tax benefit related to intellectual property transfers, resulting in a reported net income of $4.700 billion. Management, however, emphasizes adjusted net income of $2.234 billion for a clearer view of underlying operational performance. Boston Scientific's strategic imperatives focus on strengthening category leadership, expanding into high-growth adjacencies, and driving global expansion, supported by continued investment in research and development. The company maintains a strong balance sheet and adequate liquidity, though it navigates an evolving healthcare landscape with pricing pressures and regulatory changes, particularly the upcoming EU MDR implementation.
Feb 25, 2020
2018
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2018
Boston Scientific Corporation (BSX) reported strong net sales growth of 8.6% for fiscal year 2018, reaching $9.823 billion. This growth was driven by an 8.0% operational increase, supplemented by favorable foreign currency fluctuations. The company's strategy focuses on strengthening category leadership, expanding into high-growth adjacencies, driving global expansion, and developing key capabilities. Key product areas contributing to this performance include Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, and Urology and Pelvic Health, with notable growth in structural heart therapies and neuromodulation. The company completed several strategic acquisitions in 2018, including Augmenix, Claret Medical, and NxThera, to enhance its product portfolio and market position. Financially, Boston Scientific reported a significant increase in net income to $1.671 billion ($1.19 per diluted share) in 2018, compared to $104 million ($0.08 per diluted share) in 2017. This improvement was supported by operational growth and a reduction in certain charges, though the company also noted significant investments in research and development and ongoing restructuring initiatives. Looking ahead, the company is pursuing the acquisition of BTG plc, expected to close in the first half of 2019, which is anticipated to further bolster its offerings in minimally invasive procedures for cancer and vascular diseases.
Feb 19, 2019
2017
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2017
Boston Scientific Corporation (BSX) reported significant progress in its 2017 fiscal year, demonstrating robust revenue growth driven by strong performance across its diverse product portfolio. The company's strategic imperatives, including strengthening category leadership and expanding into high-growth adjacencies, appear to be yielding positive results, as evidenced by increases in net sales across multiple business segments like Interventional Cardiology, Peripheral Interventions, and MedSurg. Acquisitions, such as Symetis SA and EndoChoice Holdings, Inc., also contributed to this growth, with ongoing integration efforts expected to further enhance market position. Financially, BSX navigated a complex market, managing expenses effectively while continuing to invest in research and development. While the company reported a net income of $104 million ($0.08 per diluted share) on a GAAP basis, adjusted net income (excluding certain charges and credits) was significantly higher at $1.752 billion ($1.26 per diluted share), highlighting the impact of significant non-recurring items, including litigation-related charges and the Tax Cuts and Jobs Act. The company maintained investment-grade credit ratings and demonstrated strong cash flow from operations, supporting its liquidity and capital resource needs. Investors should note the substantial ongoing litigation reserves and the company's strategic focus on innovation and market expansion.
Feb 20, 2018
2016-A
BOSTON SCIENTIFIC CORP Annual Report (Amendment), Year Ended Dec 31, 2016
This filing is Amendment No. 1 (Form 10-K/A) to Boston Scientific's annual report for the fiscal year ended December 31, 2016. It contains no financial statements, business description, MD&A, or risk factors. Its only purpose is to correct a typographical error in Exhibit 23, the Consent of Independent Registered Public Accounting Firm (Ernst & Young LLP), which did not conform to the consent the auditors provided. The company states there are no other changes to the Form 10-K, and the amendment speaks only as of the original filing date, February 23, 2017. For investors, this amendment carries no new financial information and does not change any disclosure in the original 10-K. The cover page does provide basic market data: about 1.363 billion common shares outstanding as of January 31, 2017, and an aggregate market value held by non-affiliates of roughly $31.6 billion, based on a June 30, 2016 closing price of $23.37 on the NYSE. The company is a large accelerated filer headquartered in Marlborough, Massachusetts. Investors seeking operating results, segment performance, or guidance should review the original 10-K filed February 23, 2017.
Mar 17, 2017
2016
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2016
Boston Scientific Corporation (BSX) reported significant net sales growth of 12% in 2016, reaching $8.386 billion. This growth was driven by strong performance across its key business segments, notably Urology and Pelvic Health (45% increase, bolstered by acquisitions) and Interventional Cardiology (12% increase, driven by drug-eluting stents and structural heart products). The company's strategic focus on innovation and market expansion appears to be yielding positive financial results, with adjusted net income showing a substantial increase. However, the report also highlights significant litigation-related charges, particularly from transvaginal surgical mesh cases, which impacted reported net income. The company continues to invest heavily in research and development, underscoring its commitment to future growth through new product introductions and technological advancements. Despite facing competitive pressures and regulatory complexities inherent in the medical device industry, Boston Scientific demonstrated solid operational execution and revenue generation in 2016.
Feb 23, 2017
2015
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2015
Boston Scientific Corporation (BSX) reported fiscal year 2015 net sales of $7.477 billion, a slight increase of 1% year-over-year. However, excluding the significant negative impact of foreign currency fluctuations ($505 million), net sales grew by a more robust 8%. This growth was driven by strong performance in its Peripheral Interventions, Urology and Pelvic Health (bolstered by the August 2015 acquisition of the American Medical Systems male urology portfolio), and Neuromodulation businesses. The company reported a net loss of $239 million ($0.18 per share) for the year. This loss was substantially impacted by significant non-GAAP adjustments, including substantial litigation-related charges ($1.105 billion), acquisition- and divestiture-related charges, and restructuring costs. Excluding these items, adjusted net income was $1.267 billion ($0.93 per share). The company continues to invest in its strategic imperatives, focusing on strengthening execution, expanding into high-growth adjacencies through strategic acquisitions, driving global expansion, managing costs, and developing key capabilities. The acquisition of the AMS male urology portfolio for $1.616 billion was a key strategic move in 2015, expanding its Urology and Pelvic Health segment. Boston Scientific also made progress in its key product launches and pipeline development, including the WATCHMAN device in the U.S. and its Lotus Valve System in Europe. Financially, the company's debt levels increased to $5.677 billion primarily due to funding acquisitions. While operating cash flow decreased significantly in 2015 due to litigation-related payments, the company maintained its investment-grade credit ratings. Investors should monitor the resolution of ongoing litigation and the company's ability to integrate its recent acquisitions effectively while managing its debt.
Feb 24, 2016
2014
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2014
Boston Scientific Corporation's (BSX) 2014 10-K filing highlights a year of revenue growth and strategic acquisitions, alongside significant litigation charges. Net sales increased by 3% to $7.38 billion, driven by strong performance in Interventional Cardiology, Electrophysiology, Endoscopy, and Peripheral Interventions. However, the company reported a net loss of $119 million, largely impacted by a $600 million settlement with Johnson & Johnson related to the Guidant acquisition. Excluding these and other charges, adjusted net income was $1.13 billion, or $0.84 per share. The company continued to execute its five strategic imperatives: strengthening execution to grow share, expanding into high-growth adjacencies, driving global expansion, funding growth initiatives, and developing key capabilities. Key acquisitions during the year included the Interventional Division of Bayer AG and IoGyn, Inc., aimed at strengthening the company's product portfolio and market position. BSX emphasizes its commitment to innovation, investing $817 million in R&D. The company also returned value to shareholders through $125 million in share repurchases. Despite ongoing healthcare policy changes and pricing pressures, Boston Scientific maintains an optimistic outlook, focusing on its diverse product portfolio and strategic growth opportunities.
Feb 25, 2015
2013
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2013
Boston Scientific Corporation's 2013 10-K filing reveals a year of strategic recalibration, with net sales slightly decreasing year-over-year to $7.143 billion. This dip was influenced by foreign currency fluctuations and the ongoing impact of divested businesses. However, on a constant currency and adjusted basis, the company saw underlying growth driven by its Endoscopy, Neuromodulation, and Peripheral Interventions segments. The company reported a net loss of $121 million for the year, largely due to significant goodwill and intangible asset impairment charges, restructuring costs, and litigation expenses. Despite these headwinds, Boston Scientific demonstrated a commitment to innovation with new product launches and continued investment in research and development, including advancements in coronary stent systems like the Promus PREMIER™ and the SYNERGY™ system. The company also made strides in its structural heart therapy and cardiac rhythm management segments, highlighting a focus on expanding its less-invasive medical device portfolio.
Feb 26, 2014
2012-A
BOSTON SCIENTIFIC CORP Annual Report (Amendment), Year Ended Dec 31, 2012
Boston Scientific Corporation's (BSX) 2012 annual report (filed February 2013) highlights a company navigating both challenges and opportunities in the medical device sector. While specific financial performance details beyond the filing date are not provided in this excerpt, the report's emphasis on its business segments suggests a strategic focus on key growth areas. Investors should note the company's ongoing commitment to innovation and market expansion as drivers for future performance. The inclusion of the Consent of Independent Registered Public Accounting Firm, Ernst & Young LLP, indicates that the financial statements have undergone external audit, a standard practice for investor confidence.
Feb 26, 2013
2012
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2012
Boston Scientific Corporation's 2012 10-K filing reveals a year of significant restructuring and a focus on key growth areas, despite a net loss driven by substantial goodwill and intangible asset impairment charges totaling $4.492 billion. The company generated $7.249 billion in net sales, a 5% decrease from 2011, primarily due to declines in the Interventional Cardiology and Cardiac Rhythm Management (CRM) segments. However, the Endoscopy and Peripheral Interventions businesses showed growth. Strategic acquisitions in 2012, including Cameron Health (S-ICD system), BridgePoint Medical, Rhythmia Medical, and Vessix Vascular, demonstrate a commitment to expanding the product portfolio in high-growth adjacencies. The company also reported progress on its restructuring initiatives aimed at improving operational efficiency and cost structure. Despite the reported net loss, adjusted net income was $933 million. Key financial metrics like operating cash flow ($1.260 billion) and maintaining investment-grade credit ratings highlight underlying operational strengths. The company's strategy emphasizes strengthening execution, expanding into high-growth areas, driving global expansion, and managing costs effectively.
Feb 22, 2013
2011
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2011
Boston Scientific Corporation's (BSX) 2011 Form 10-K highlights a year of strategic repositioning and operational adjustments. The company reported net sales of $7.62 billion, a slight decrease from the prior year, impacted by the divestiture of its Neurovascular business. Despite the sales decline, adjusted net income remained robust, reflecting successful cost-containment measures and restructuring initiatives aimed at improving operational efficiency and profitability. The company continued to invest in research and development, focusing on innovation across its key business segments, including Interventional Cardiology, Cardiac Rhythm Management (CRM), Endoscopy, and Peripheral Interventions. Key financial and operational themes for 2011 include managing pricing pressures in core markets like coronary stents and CRM, investing in emerging markets, and navigating a complex regulatory and reimbursement environment. The company made significant strides in debt reduction, improving its credit ratings, and repurchased a substantial amount of its common stock. Despite facing challenges such as competition and evolving healthcare policies, Boston Scientific emphasized its commitment to innovation and delivering value to patients and shareholders through its diversified portfolio of less-invasive medical devices.
Feb 17, 2012
2010
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2010
Boston Scientific's FY2010 10-K (filed February 17, 2011) shows a year of significant strain: net sales fell 5% to $7.806 billion, and the company posted a GAAP net loss of $1.065 billion ($0.70 per share). The loss was driven primarily by a $1.817 billion goodwill impairment on the U.S. Cardiac Rhythm Management (CRM) unit, which followed the March 2010 ship hold and removal of field inventory of its ICD and CRT-D defibrillators. Excluding these and other non-GAAP items, adjusted net income was $1.051 billion, or $0.69 per share. Operating cash flow fell to $325 million, reduced by about $1.6 billion of litigation payments, most notably the $1.725 billion Johnson & Johnson patent settlement. The balance sheet is still heavily levered, with total debt of $5.438 billion, and the company is working to reduce it. In January 2011 it closed the $1.5 billion sale of its Neurovascular business to Stryker, prepaid $250 million of senior notes and pre-paid part of its term loan, and announced or completed several acquisitions (Sadra Medical, Intelect Medical, and Atritech) to expand into structural heart, deep-brain stimulation, and atrial fibrillation. Management also flagged significant risks: continued pricing pressure on drug-eluting stents (U.S. average selling prices down about nine percent), loss of defibrillator share, goodwill impairment exposure in four reporting units holding roughly $9 billion of goodwill, the 2.3% medical device excise tax beginning in 2013, and ongoing patent and government investigations. The company paid no dividend and does not plan to, prioritizing debt repayment. For investors, the central questions are whether CRM share can be recaptured, whether the stent franchise can stabilize as next-generation Element platforms launch, and whether asset sales and cost restructuring can meaningfully reduce leverage and litigation overhang.
Feb 17, 2011
2009
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2009
Boston Scientific's 2009 10-K shows a company in transition: net sales rose 2% to $8.188 billion (up 4% excluding currency and divested businesses), but the reported net loss of $1.025 billion ($0.68 per share) was driven by large litigation charges, chiefly the $2.022 billion of litigation-related net charges in 2009, including the $1.725 billion settlement with Johnson & Johnson. Gross margin fell to 68.5% from 69.3%, largely because lower-margin Abbott-supplied PROMUS everolimus stents displaced higher-margin TAXUS sales, and drug-eluting stent pricing pressure and a 2008 $2.613 billion goodwill impairment weigh on the balance sheet, which shows $12.4 billion of goodwill and $6.7 billion of other intangibles against $12.3 billion of equity. The balance sheet and liquidity picture is the central investor concern. Total debt was $5.918 billion against $864 million of cash, and roughly $1.75 billion of debt plus the revolver matures in 2011, with management targeting a refinancing by mid-2010. Operating cash flow fell to $835 million from $1.216 billion, reflecting litigation payments. Standard & Poor's upgraded the company to BBB- (investment grade), while Moody's (Ba1) and Fitch (BB+) remain below investment grade. Remaining J&J payments of about $725 million are due by January 2011. Management is responding with a February 2010 restructuring plan (integrating the CRM and Cardiovascular groups, centralizing R&D, and cutting roughly 1,000 to 1,300 positions, with $200 to $250 million of targeted annual savings by 2011) and a Plant Network Optimization program. Key risks include declining U.S. ICD market growth, competitive pressure on drug-eluting stents, an Abbott supply dependence through mid-2012, FDA warning-letter status, extensive ongoing litigation and government investigations, and proposed medical device taxes.
Feb 26, 2010
2008
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2008
Boston Scientific Corporation's (BSX) 2008 10-K filing reveals a challenging year marked by a significant net loss primarily driven by substantial goodwill and intangible asset impairment charges totaling $2.79 billion. This impairment was largely attributed to the impact of disruptions in the credit and equity markets following the 2006 Guidant acquisition. Despite the net loss, the company generated robust operating cash flow of $1.216 billion, demonstrating operational resilience. Net sales saw a slight decrease of 4% to $8.05 billion, impacted by increased competition in the drug-eluting stent market and the divestiture of non-strategic businesses. However, growth was observed in the Cardiac Rhythm Management (CRM) segment, up 8%, and Endosurgery, up 8%, highlighting strategic product launches and market penetration. The company is actively managing its financial position by reducing debt, having prepaid $1.425 billion under its term loan and credit facility in 2008. Furthermore, Boston Scientific is implementing cost-saving measures, including a plant network optimization plan aimed at simplifying manufacturing and improving gross margins. The company's product portfolio remains strong, with continued investment in innovation for both CRM and cardiovascular devices. Key risks highlighted include intense competition, regulatory scrutiny, and the ongoing impact of economic downturns on healthcare spending and reimbursement.
Feb 27, 2009
2007
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2007
Boston Scientific Corporation's (BSX) 2007 10-K filing reveals a year of significant strategic restructuring, marked by sales of non-core businesses and a focus on optimizing operations. Despite a reported net loss of $495 million, the company's net sales grew 7% to $8.36 billion, largely driven by the acquisition of Guidant Corporation, which bolstered its Cardiac Rhythm Management (CRM) segment. However, sales in the crucial coronary stent business saw a notable decline of 19%, primarily due to market concerns surrounding late stent thrombosis and decreased procedural volumes. The company is actively managing its debt, which stood at $8.19 billion at year-end 2007, and is implementing cost-reduction initiatives aimed at improving financial performance and focusing on core growth areas. The company's strategic initiatives included divesting five non-strategic businesses, leading to approximately 2,000 job reductions. These actions are intended to streamline operations and improve financial flexibility. Despite the reported net loss, the company's operational cash flow remained positive at $934 million, and it continues to invest in research and development, albeit with a strategic realignment to focus on key product lines like drug-eluting stents and CRM technologies. Management is focused on navigating the challenges in the drug-eluting stent market and rebuilding confidence in its CRM offerings while working to resolve outstanding FDA matters.
Feb 28, 2008
2006
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2006
Boston Scientific Corporation (BSX) reported its 2006 annual results, a year marked by the transformative acquisition of Guidant Corporation. This acquisition significantly expanded BSX's footprint, particularly in the Cardiac Rhythm Management (CRM) and Cardiac Surgery sectors, establishing it as a major player in cardiovascular devices. While the Guidant acquisition drove a substantial increase in net sales to $7.821 billion, the company reported a net loss of $3.577 billion for the year, primarily due to significant one-time acquisition-related charges, including purchase accounting adjustments and integration costs. The company faced challenges in its core coronary stent business, with sales declining due to market concerns over late stent thrombosis, although regulatory panels continued to affirm the safety and efficacy of drug-eluting stents. Despite the reported net loss, the company generated strong operating cash flow and maintained a focus on innovation and quality improvement. The integration of Guidant presented both opportunities and challenges, with ongoing restructuring efforts planned to optimize operations. BSX also addressed regulatory issues, including FDA warning letters at several facilities, and made progress on remediation efforts. Looking ahead, the company aimed to leverage its expanded product portfolio, particularly in the CRM and drug-eluting stent markets, while managing its debt obligations incurred from the Guidant acquisition.
Mar 1, 2007
2005
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2005
Boston Scientific's FY2005 10-K shows a company at an inflection point. Net sales rose 12% to $6,283 million, and gross margin improved to 77.9%, driven largely by TAXUS drug-eluting stent sales of $2,556 million (about 41% of revenue). However, reported net income fell 41% to $628 million ($0.75 per diluted share) from $1,062 million, primarily because of a $780 million pre-tax litigation charge tied to the $750 million Medinol settlement, along with $276 million of purchased R&D from acquisitions. Operating cash flow dropped to $903 million from $1,804 million, and net debt rose to $1,172 million from $727 million. The central risk for investors is the U.S. drug-eluting stent franchise. Management reported that U.S. TAXUS share declined sequentially through the first three quarters of 2005 before stabilizing in Q4, and pricing pressure is increasing. Competitors are entering internationally now and are expected in the U.S. in the second half of 2007. The company also received an FDA corporate warning letter on January 26, 2006, citing quality-system deficiencies at three facilities, which could affect exports and class III premarket approvals, including the planned U.S. launch of TAXUS Liberté in the second half of 2006. The filing is dominated by the pending $27 billion acquisition of Guidant Corporation, expected the week of April 3, 2006, with Abbott acquiring Guidant's vascular businesses and sharing a second drug-eluting stent program. The deal requires roughly $8 billion of new cash borrowings and will be followed by a credit downgrade, an interest-rate step-up on certain senior notes, and significant EPS dilution. Weighted diluted shares are expected to rise from about 840 million to about 1.4 billion. Investors should weigh the diversification into cardiac rhythm management against higher leverage, integration risk, and Guidant's product-recall and government-investigation overhang.
Mar 1, 2006
2004
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2004
Boston Scientific Corporation's 2004 10-K report highlights a year of significant growth, driven primarily by the strong performance of its TAXUS® Express 2™ paclitaxel-eluting coronary stent system. Net sales surged by 62% to $5.62 billion, with the TAXUS stent system alone accounting for 38% of total net sales, underscoring its critical role in the company's revenue. The company is strategically positioned to capitalize on the expanding drug-eluting stent market, which it anticipates will constitute the majority of the coronary stent market in the coming years. Boston Scientific is also actively investing in its research and development pipeline, pursuing next-generation technologies and expanding into new therapeutic areas such as neuromodulation through its acquisition of Advanced Bionics Corporation. While the company faces ongoing patent litigation and competitive pressures, its focus on innovation, product diversity, and operational excellence aims to sustain its market leadership.
Mar 16, 2005
2003
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2003
Boston Scientific's 2003 10-K shows a company in transition, with growth driven by its TAXUS paclitaxel-eluting coronary stent. Net sales rose 19% (14% at constant currency) to $3,476 million from $2,919 million, and gross margin expanded 220 basis points to 72.4%. Net income was $472 million, or $0.56 per diluted share, versus $373 million ($0.45) in 2002. Operating cash flow was a solid $787 million, and EBITDA reached $879 million. Management guided to significant revenue, earnings, and cash flow growth in 2004 as TAXUS launched in the U.S. in Q1 2004, and noted the company is one of only two drug-eluting stent products in the U.S. market. The filing also highlights meaningful risks. The U.S. drug-eluting stent market is becoming more competitive after Guidant and Johnson & Johnson's Cordis alliance, and physician adoption, pricing, and inventory management remain uncertain. Boston Scientific carries extensive patent litigation with Johnson & Johnson/Cordis, Medinol, Medtronic, and others, and it settled its disputes with Guidant in February 2004. Balance sheet leverage rose: net debt increased to $973 million from $658 million, largely to fund TAXUS, acquisitions, strategic alliances, and a $570 million share buyback. The company also disclosed that the U.S. Department of Justice investigation continues, with the company and two senior officials identified as targets of a federal grand jury, which could extend into mid-2004 or beyond. For investors, the central question is whether TAXUS can convert its strong early international share into durable U.S. leadership and margin expansion, weighed against rising competition, litigation exposure, and the open DOJ investigation.
Mar 15, 2004
2002
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2002
Boston Scientific reported a strong 2002 rebound. Net sales rose 9% to $2,919 million, with U.S. sales up 10% to $1,756 million and international sales up 8% to $1,163 million. Reported net income was $373 million, or $0.90 per diluted share, compared with a net loss of $54 million in 2001. Excluding after-tax special items, net income was $413 million, or $1.00 per diluted share, versus $323 million ($0.80) in 2001. Gross margin improved to 70.2% (71.2% excluding special items), helped by the global operations plan, which delivered about $220 million of pre-tax savings in 2002. Cash from operations nearly tripled to... no, rose 50% to $736 million, and net debt fell to $658 million from $1,024 million. The central investment theme is the drug-eluting stent (DES) opportunity. Coronary stent sales fell 8% to $318 million because of weak physician acceptance of the NIR stent, particularly in Japan. The company relaunched its Express2 bare-metal stent in the U.S. in September 2002, lifting its domestic coronary stent share above 20% in the fourth quarter. The TAXUS paclitaxel-eluting stent was filed with the FDA in modules, with the full PMA expected by mid-2003 and a U.S. launch targeted for late 2003. Management expects research and development spending to stay near 12% of sales in 2003, including about $100 million for the TAXUS program. The filing also flags substantial risks: intense patent litigation with Johnson and Johnson/Cordis, Guidant and Medinol, a U.S. Department of Justice grand jury investigation in which the company and two senior officials are identified as targets, and the possibility of share and price pressure in U.S. coronary stents before TAXUS launches.
Mar 31, 2003
2001
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2001
Boston Scientific's 2001 results were weak on a reported basis. Net sales were essentially flat at $2,673 million (vs. $2,664 million in 2000, up about 4% excluding roughly $92 million of currency headwinds), but the company posted a reported net loss of $54 million, or $0.13 per share, versus net income of $373 million in 2000. The loss was driven by $377 million of after-tax charges, chiefly $282 million of purchased in-process R&D from 2001 acquisitions, a provision for excess NIR stent inventory, costs of the global operations plan, and an intangible asset write-down. Excluding these charges, net income was $323 million, or $0.80 per share diluted, down from $1.03 in 2000 on an adjusted basis. The core investment question is the coronary stent franchise. NIR stent sales fell to about 11% of sales from 15% in 2000, with fourth-quarter NIR sales roughly half of first-quarter levels, and management expects further share erosion in 2002. Management is betting on the internally developed Express stent (launched in Europe in late 2001, U.S. launch expected in the second half of 2002) and the TAXUS paclitaxel-eluting stent (international launch planned for 2002, U.S. launch targeted for late 2003). Research and development spending rose to $275 million, about 10% of sales, and will increase further in 2002. Gross margin, excluding special items, improved modestly to 69.8%. The balance sheet remains manageable, with total assets of $3.97 billion, stockholders' equity of $2.02 billion, and total debt of roughly $1.1 billion. Operating cash flow fell to $490 million from $739 million. Risk factors are substantial: an open Johnson & Johnson patent verdict on the NIR stent that could imply up to about $324 million in damages plus interest, a $169 million arbitration award against Medtronic AVE under appeal, an ongoing dispute with supplier Medinol that could disrupt NIR supply, and a pending FTC matter. Investors should weigh the potential of the Express and TAXUS platforms against near-term stent erosion, litigation exposure, and the execution risk of integrating several 2001 acquisitions.
Mar 27, 2002
2000
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2000
Boston Scientific's fiscal 2000 10-K shows a company under pressure but with a clear recovery plan. Net sales fell 6% to $2,664 million from $2,842 million, driven mainly by a 9% decline in U.S. revenue as coronary stent sales dropped from $604 million to $427 million and balloon sales from $429 million to $357 million. Net income was $373 million, or $0.91 diluted EPS, roughly flat versus $371 million in 1999, and operating income of $580 million fell from $689 million. Gross margin improved to 68.8% from 65.3%, largely because 1999 carried a $62 million NIR stent inventory charge, but SG&A rose to 33% of sales from 30%, reflecting sales force retention and international expansion costs. The main investor concerns are the NIR stent franchise and legal exposure. Coronary stents depend heavily on Medinol, which supplies the NIR stent, and management describes that relationship as contentious. A December 2000 jury found the NIR stent infringed one Cordis (Johnson & Johnson) patent, and the Company could owe about $324 million plus interest, with a range of $0 to $344 million disclosed for reasonably possible losses. The company also faces a DOJ investigation tied to the NIR ON Ranger recall, an FTC suit, and securities class actions. Management is responding with a global operations plan targeting about $100 million of pre-tax savings in 2001 and $250 million annualized thereafter, plus acquisitions of IVT, Embolic Protection, Quanam and Catheter Innovations, which carry $100 million to $200 million in expected contingent payments in 2001. Management guides to lower 2001 operating margins, higher R&D spending, and gross margin pressure from more expensive gold-coated stents. Balance sheet strength is adequate. Total assets were $3,427 million and stockholders' equity was $1,935 million, with long-term debt down to $562 million and the debt-to-capitalization covenant at about 26% against a 60% limit. Share repurchases of $222 million and the planned acquisition spending will test free cash flow, which was $739 million in operating cash flow less $76 million of capex in 2000.
Apr 2, 2001
1998-A2
BOSTON SCIENTIFIC CORP Annual Report (Amendment), Year Ended Dec 31, 1998
Boston Scientific's 1998 results were dominated by the September 1998 acquisition of Schneider Worldwide for $2.1 billion in cash, which drove a swing to a net loss of $264 million, or $0.68 per diluted share, from net income of $110 million, or $0.28, in 1997. Net sales grew 22% to $2.23 billion, with U.S. sales up about 30% helped by the third-quarter launch of the NIR coronary stent. However, the headline loss was driven by a $671 million (pre-tax) write-off of purchased in-process R&D tied to Schneider, plus $31 million for a NIR stent recall and restructuring items. Excluding merger-related and special charges, net income was $262 million, or $0.66 per share, roughly flat with 1997. Underlying profitability weakened. Gross margin fell to 67.1% from 70.2%, reflecting inventory write-downs, pricing pressure from managed care, and the lower-margin NIR stent mix. Management attributes the margin pressure partly to a weakened supply chain from multiple acquisitions and has launched a global supply chain program expected to finish by year-end 1999. Operating cash flow was $258 million, but working capital swung to a deficit of $353 million, and the balance sheet took on $1.36 billion of long-term debt plus about $1.0 billion of commercial paper, which pushed the debt-to-capitalization ratio to roughly 64% against a covenant maximum of 70% through 1999 and 60% thereafter. Investors should weigh several risks. The company plans to raise equity and convertible securities in 1999 to refinance credit facilities and comply with its debt covenant, and $1.2 billion of 364-day facilities expire in September 1999. The SEC is reviewing the Schneider in-process R&D allocation and could require restatement, and a Japanese subsidiary revenue-recognition irregularity has triggered 16 shareholder class actions and a DOJ investigation. Patent litigation with Johnson & Johnson, Cordis, and Advanced Cardiovascular Systems is ongoing.
Jun 2, 1999
1998-A
BOSTON SCIENTIFIC CORP Annual Report (Amendment), Year Ended Dec 31, 1998
Boston Scientific's 1998 results were dominated by the September 1998 acquisition of Schneider Worldwide (from Pfizer) for about $2.1 billion in cash, which drove a sharp swing to a net loss of $264 million, or $0.68 per diluted share, from net income of $110 million, or $0.28, in 1997. Net sales rose 22% to $2.23 billion, with U.S. sales up roughly 30% on the launch of the NIR coronary stent, while international sales grew about 11%. Operating results were hit by a $671 million charge for purchased in-process R&D, $527 million after tax in total special charges, and a $31 million recall provision for the NIR ON Ranger with Sox stent. Excluding merger-related and special charges, net income was $262 million, or $0.66 per share, roughly flat versus 1997. Gross margin fell to 67.1% from 70.2%, reflecting supply chain problems, pricing pressure, and the lower-margin NIR stent mix. The balance sheet and liquidity picture weakened considerably. Total assets nearly doubled to $3.89 billion, and stockholders' equity fell to $821 million from $957 million. Commercial paper of about $1.8 billion was used to fund the acquisition, and the company refinanced much of it in Q1 1999 with short-term borrowings under its revolving credit facilities at roughly 5.75%. Working capital was negative $353 million. The revolving facilities carry a debt-to-capitalization covenant of 70% through 1999 (the company reported about 64%), and $1.2 billion of 364-day facilities expire in September 1999. Management intends to raise equity and convertible securities in 1999 to refinance debt and restore covenant headroom, so further dilution is likely. Investors also face significant regulatory and legal risk. A Japanese subsidiary's revenue-recognition irregularities led to 16 shareholder class actions and prompted restated 1998 quarterly results. The SEC is reviewing the Schneider purchased in-process R&D allocation and could require restatement of prior results, potentially affecting future EPS. The Department of Justice is investigating the NIR stent recall, and the company faces numerous patent suits, including a $10.8 million judgment to C.R. Bard. Management expects integration and rationalization to conclude in 1999, with roughly 2,000 positions displaced and cost savings of $50 to $75 million projected. This is a 10-K/A that supplements MD&A and the notes; it does not change the reported financial statements.
Apr 28, 1999
1997-A
BOSTON SCIENTIFIC CORP Annual Report (Amendment), Year Ended Dec 31, 1997
Boston Scientific's amended 1997 Form 10-K/A (filed March 1999) centers on a restatement triggered by business irregularities discovered in its Japanese subsidiary in November 1998. Restated 1997 net sales were $1,831 million, down from $1,872 million previously reported, and net income was $110 million versus $139 million previously. The restatement also reduced quarterly 1998 comparisons, so investors should treat the restated figures as the reliable baseline for period-to-period analysis. Reported 1997 results were also weighed down by $259 million in merger-related and special charges, tied largely to the Target Therapeutics pooling merger and inventory write-downs, which kept excluding-charges net income growth to roughly 2%. Underlying operations showed strong top-line momentum: net sales rose 18% (about 23% excluding currency), international sales reached 41% of the total, and vascular and nonvascular sales grew 16% and 26%. However, profitability pressures were visible. Gross margin fell to 70.2% from 72.4%, mainly due to inventory write-downs and pricing pressure, and SG&A rose 35% to 38% of sales. Working capital fell from $335 million to $227 million, operating cash flow dropped from $142 million to $80 million, and inventory grew $155 million, largely to stock the NIR stent ahead of its planned U.S. and Japan launch. The company also issued $500 million of public debt in March 1998 to repay commercial paper. Key forward-looking risks include the timing of NIR stent FDA approval, ongoing patent litigation (including suits with Johnson & Johnson, Cordis, and Advanced Cardiovascular Systems), completion of Target integration by end-1998, foreign currency exposure, and healthcare cost-containment pressure from managed care and group purchasing organizations. The restatement itself raises governance and internal-control questions that investors should weigh alongside the operating picture.
Mar 31, 1999
1998
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 1998
Boston Scientific's 1998 10-K shows a company in transition. Net sales rose 22% to $2.23 billion, driven by the September 1998 acquisition of Schneider Worldwide ($2.1 billion in cash) and strong U.S. coronary stent sales led by the NIR stent. However, the company reported a net loss of $264 million, or $(0.68) per diluted share, because of a $671 million non-cash purchased in-process R&D charge tied to Schneider and about $667 million in total special charges. Excluding those items, net income was roughly $262 million, or $0.66 per share, versus $0.67 in 1997, so underlying earnings were essentially flat. The balance sheet and liquidity picture is the main concern for investors. Working capital turned to a deficit of $353 million, long-term debt reached $1.36 billion, and the company refinanced its commercial paper into 364-day revolving facilities expiring in September 1999. Management said it intends to raise equity and convertible securities in 1999 and acknowledged that an extension of the facilities will be needed if it does not obtain additional financing. The company also reported an accounting irregularity at its Japanese subsidiary, which led to securities class actions, and a U.S. Department of Justice investigation tied to the recall of the NIR ON Ranger with SOX stent. Gross margin fell to 67.1% from 70.2%, and a global supply chain program is intended to recover it. Leadership also changed, with James R. Tobin appointed President and CEO on March 18, 1999.
Mar 31, 1999
1997
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 1997
Boston Scientific's 1997 10-K shows a company with strong top-line growth but a difficult year on profitability and execution. Net sales rose 21% to $1.87 billion (about 26% excluding currency effects), with international sales reaching 43% of the total. However, reported net income fell to $139 million ($0.70 diluted EPS) from $167 million, weighed down by $259 million of merger-related and special charges, a $21 million accounting change for EITF 97-13, and inventory write-downs. Excluding special items, net income rose 12% to $331 million. Management attributed the margin pressure to European and Japanese reimbursement cuts, unfavorable currency movements (about $82 million of negative impact), supply chain and legacy systems problems, and rising inventory and receivables that pushed days sales outstanding to 77 from 68. Balance sheet and cash flow deserve investor attention. Cash from operations fell to $80 million from $142 million, inventory rose $150 million (much of it NIR stent stock ahead of an expected 1998 U.S. launch), and commercial paper climbed to $423 million. The company issued $500 million of 6.625% notes due 2005 in March 1998 to repay commercial paper. Gross margin fell to 70.6% from 72.4%, and the company expects operating expense growth to outpace sales through the first half of 1998. Investment in the business is heavy, with R&D at $167 million (about 9% of sales) and capex planned at roughly $230 million for 1998. The outlook depends largely on regulatory timing. The NIR and Radius coronary stents are awaiting FDA approval, and the company is also defending several significant patent suits, including Circon, Cordis, Johnson & Johnson, and Advanced Cardiovascular Systems. Management acknowledges that integration of Target Therapeutics runs through the end of 1998 and that execution risk remains significant.
Mar 31, 1998
1996
BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 1996
Boston Scientific's 1996 10-K shows a company that grew sharply through acquisitions but whose reported profitability was heavily affected by one-time charges. Net sales rose 29.5% to $1.46 billion from $1.13 billion, and vascular products (about 78% of sales) drove most of the growth. Net income rose to $167 million, or $0.92 per share, from $6 million in 1995. Excluding special charges tied to 1995 and 1996 acquisitions, management reports net income of $281 million, up 39%. Gross margin improved to about 72.6% from 71.2%, and international sales grew to 39% of revenue, though foreign exchange was a drag. The balance sheet is more stretched than the income statement suggests. Cash and short-term investments fell to about $81 million from $161 million, commercial paper of $212.5 million was issued in 1996, and intangibles rose to $308 million from $138 million, largely from acquisitions. Operating cash flow of $134 million covered only part of the roughly $200 million of planned 1997 capital expenditures, and integration of the 1995 and 1996 deals is not expected to finish until the end of 1997. Management also flagged risks around managed-care pricing pressure, the integration effort, and the pending Target Therapeutics merger, which is expected to close in the second quarter of 1997 as a pooling-of-interests transaction. Legal exposure is significant and active. The company is in multiple patent disputes, including a Bard infringement suit filed in February 1997 and a broad European litigation campaign against Johnson & Johnson over the NIR stent. The company also faces a federal OIG investigation into reimbursement for devices that were not FDA-approved at the time of use. Management says none of these matters is expected to be material, but it acknowledges that adverse patent outcomes could be material.
Mar 31, 1997